. 2020 Jul 30;41(10):1368–1384. doi: 10.1093/carcin/bgaa080

Table 4.

Multivariable-adjusted HRs and 95% CI for the relation between nut and peanut butter intake and the risk of molecular subtypes of CRC in women; NLCS, 1986–1993, excluding the first 2.3 years of follow-up

	Total nuts (g/day)					Tree nuts (g/day)				Peanuts (g/day)					Peanut butter (g/day)
	0.0	0.1–<5/0.1+	5+	P-trend/FDR- adjusted P-trend^b	Per 5 g/day increment	0.0	0.1+	P-trend/FDR- adjusted P-trend^b	Per 5 g/day increment	0.0	0.1–<5/0.1+	5+	P-trend/FDR- adjusted P-trend^b	Per 5 g/day increment	0.0	0.1–<5/0.1+	5+	P-trend/FDR- adjusted P-trend^b	Per 5 g/day increment
Person-years in subcohort	3641	3295/5443	2149			6378	2706			4287	3360/4797	1437			6643	1599/2441	842
Total CRC
N cases	110	104	48			194	68			125	104	33			194	48	20
HR^a	1	1.15	0.87	0.339/	0.97	1	0.89	0.487/	0.95	1	1.19	0.92	0.658/	0.98	1	1.13	0.95	0.882/	0.92
95% CI	ref	0.85–1.56	0.59–1.28	0.875	0.86–1.10	ref	0.65–1.22	0.875	0.73–1.23	ref	0.89–1.61	0.60–1.42	0.922	0.86–1.11	ref	0.80–1.60	0.57–1.59	0.970	0.73–1.16
APC wild-type
N cases	77	68	35			135	45			86	94				129	51
HR^a	1	1.10	0.94	0.716/	1.00	1	0.88	0.483/	0.94	1	1.15		0.397/	1.02	1	1.28		0.165/	1.07
95% CI	ref	0.77–1.57	0.60–1.49	0.922	0.87–1.16	ref	0.61–1.27	0.875	0.65–1.35	ref	0.83–1.60		0.875	0.89–1.17	ref	0.90–1.83		0.875	0.85–1.34
Truncating APC mutation
N cases	33	36	13			59	23			39	43				65	17
HR^a	1	1.27	0.73	0.238/	0.91	1	0.94	0.827/	0.97	1	1.08		0.766/	0.88	1	0.68		0.187/	0.44
95% CI	ref	0.76–2.12	0.36–1.46	0.875	0.75–1.12	ref	0.54–1.64	0.958	0.68–1.37	ref	0.66–1.75		0.922	0.68–1.14	ref	0.38–1.21		0.875	0.22–0.90
P-hetero-geneity					0.630				0.612					0.967					0.193
KRAS wild-type
N cases	73	70	33			131	45			83	70	23			131	45
HR^a	1	1.19	0.95	0.672/	0.94	1	0.91	0.633/	0.72	1	1.22	1.02	0.987/	0.97	1	1.07		0.733/	0.93
95% CI	ref	0.84–1.71	0.60–1.52	0.922	0.82–1.07	ref	0.62–1.34	0.922	0.44–1.17	ref	0.86–1.74	0.61–1.71	0.987	0.85–1.11	ref	0.74–1.55		0.922	0.70–1.24
Activating KRAS mutation
N cases	37	34	15			63	23			42	34	10			63	23
HR^a	1	1.07	0.72	0.265/	1.02	1	0.88	0.588/	1.08	1	1.15	0.76	0.409/	0.98	1	1.08		0.775/	0.88
95% CI	ref	0.65–1.77	0.38–1.39	0.875	0.83–1.24	ref	0.54–1.41	0.922	0.94–1.25	ref	0.69–1.89	0.37–1.56	0.875	0.76–1.27	ref	0.65–1.77		0.922	0.60–1.30
P-hetero-geneity					0.956				0.837					0.947					0.847
No p53 over-expression
N cases	40	49	27			78	38			48	49	19			78	28	10
HR^a	1	1.54	1.33	0.517/	1.06	1	1.26	0.278/	1.09	1	1.52	1.35	0.391/	1.06	1	1.66	1.21	0.499/	1.04
95% CI	ref	0.98–2.42	0.78–2.27	0.875	0.95–1.20	ref	0.83–1.90	0.875	0.96–1.22	ref	0.98–2.37	0.76–2.41	0.875	0.93–1.21	Ref	1.05–2.64	0.58–2.53	0.875	0.79–1.37
p53 over-expression
N cases	68	55	21			114	30			75	55	14			115	19	10
HR^a	1	0.97	0.62	0.084/	0.82	1	0.67	0.083/	0.54	1	1.04	0.68	0.209/	0.86	1	0.75	0.78	0.444/	0.78
95% CI	ref	0.66–1.42	0.36–1.09	0.875	0.68–1.00	ref	0.43–1.05	0.875	0.25–1.18	ref	0.71–1.51	0.36–1.26	0.875	0.69–1.06	ref	0.45–1.24	0.39–1.56	0.875	0.53–1.14
P-hetero-geneity					0.069				0.028					0.166					0.063
BRAF wild-type
N cases	86	77	38			151	50			97	104				150	51
HR^a	1	1.09	0.88	0.491/	0.99	1	0.84	0.339/	0.99	1	1.10		0.562/	0.99	1	1.02		0.933/	0.86
95% CI	ref	0.78–1.53	0.57–1.37	0.875	0.87–1.13	ref	0.59–1.20	0.875	0.78–1.25	ref	0.80–1.50		0.916	0.86–1.14	ref	0.72–1.44		0.977	0.66–1.12
BRAF mutation
N cases	17	23	10			33	17			21	29				37	13
HR^a	1	1.70	1.20	0.931/	0.98	1	1.36	0.350/	0.87	1	1.47		0.222/	1.00	1	1.20		0.609/	1.08
95% CI	ref	0.88–3.28	0.53–2.74	0.977	0.79–1.20	ref	0.71–2.60	0.875	0.42–1.83	ref	0.79–2.71		0.875	0.82–1.20	ref	0.60–2.38		0.922	0.63–1.85
P-hetero-geneity					0.510				0.216					0.436					0.932
MSS
N cases	88	116				154	50			100	104				154	50
HR^a	1	0.99		0.974/	0.99	1	0.81	0.239/	1.01	1	1.05		0.754/	0.98	1	0.97		0.853/	0.91
95% CI	ref	0.73–1.36		0.987	0.86–1.13	ref	0.57–1.15	0.875	0.84–1.22	ref	0.77–1.43		0.922	0.84–1.14	ref	0.68–1.37		0.962	0.70–1.20
MSI
N cases	13	25				23	15			16	22				27	11
HR^a	1	1.74		0.136/	0.87	1	1.96	0.064/	0.52	1	1.72		0.134/	0.94	1	1.46		0.326/	0.85
95% CI	ref	0.84–3.61		0.875	0.67–1.14	ref	0.96–4.01	0.875	0.28–0.95	ref	0.85–3.50		0.875	0.74–1.20	ref	0.69–3.11		0.875	0.52–1.38
P-hetero-geneity					0.298				0.069					0.431					0.575

^aAdjusted for age (years; continuous), cigarette smoking [status (never/former/current), frequency (n/day; continuous, centered) and duration (years; continuous, centered)], BMI (kg/m²; continuous), non-occupational physical activity (≤30/>30–≤60/>60–≤90/>90 min/day), educational level (low/medium/high), family history of CRC (no/yes), total energy intake (kcal/day; continuous) and alcohol consumption (g/day; continuous).

^bFDR-adjusted P-trends are calculated with adjustment for 44 tests.